Johnson & Johnson’s JNJ‑6143 shows high PSA response rates in phase‑1 mCRPC trial
Johnson & Johnson reported results from a phase‑1 study of JNJ‑6143, a first‑in‑class oral RIPTAC that targets the androgen receptor and BRD4, in heavily pretreated metastatic castration‑resistant prostate cancer. The trial enrolled 105 men with a median of four prior systemic therapies and used a 50 mg daily dose as the recommended phase‑2 dose. At a data cutoff in September 2026, the drug showed high PSA response rates and a confirmed overall response rate in measurable disease, with no grade‑3 or higher treatment‑related adverse events at the 50 mg dose.
Why it matters
Johnson & Johnson says the data support continued development of JNJ‑6143 and progression to phase‑2 trials, which could add a novel therapeutic option in a high‑unmet‑need cancer space.
Key facts
- 1The study enrolled 105 patients with metastatic castration‑resistant prostate cancer. urotoday.com
- 2Patients had a median of four prior lines of systemic therapy. urotoday.com
- 3The recommended phase‑2 dose is 50 mg taken orally once daily. hmpgloballearningnetwork.com
- 4At the September 2026 data cutoff, median follow‑up was 5.6 months and 71% of patients remained on therapy. hmpgloballearningnetwork.com
- 5No treatment‑related adverse events of grade 3 or higher were observed at the 50 mg dose. hmpgloballearningnetwork.com
- 6A confirmed overall response rate of 69% in RECIST‑evaluable disease was reported at the data cutoff. hmpgloballearningnetwork.com
Open questions
- PSA50 response rate reported as 77% versus 71%
- PSA90 response rate reported as 48% versus 41%
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.